1. Home
  2. NBB vs BWAY Comparison

NBB vs BWAY Comparison

Compare NBB & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Taxable Municipal Income Fund of Beneficial Interest

NBB

Nuveen Taxable Municipal Income Fund of Beneficial Interest

HOLD

Current Price

$15.67

Market Cap

462.4M

Sector

Finance

ML Signal

HOLD

Logo BrainsWay Ltd.

BWAY

BrainsWay Ltd.

HOLD

Current Price

$15.89

Market Cap

450.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NBB
BWAY
Founded
N/A
2003
Country
United States
Israel
Employees
N/A
N/A
Industry
Finance Companies
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
462.4M
450.8M
IPO Year
2010
N/A

Fundamental Metrics

Financial Performance
Metric
NBB
BWAY
Price
$15.67
$15.89
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$13.25
AVG Volume (30 Days)
44.7K
139.1K
Earning Date
01-01-0001
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$309.69
Revenue Next Year
N/A
$26.21
P/E Ratio
N/A
$81.98
Revenue Growth
N/A
N/A
52 Week Low
$14.95
$8.61
52 Week High
$16.62
$26.63

Technical Indicators

Market Signals
Indicator
NBB
BWAY
Relative Strength Index (RSI) 44.97 54.62
Support Level $15.52 $14.56
Resistance Level $16.01 $16.63
Average True Range (ATR) 0.17 0.62
MACD -0.01 0.28
Stochastic Oscillator 19.05 73.44

Price Performance

Historical Comparison
NBB
BWAY

About NBB Nuveen Taxable Municipal Income Fund of Beneficial Interest

Nuveen Taxable Municipal Income Fund is a closed-end fund incorporated in the United States. Its primary objective is current income through investments in taxable municipal securities; the secondary objective is to seek enhanced portfolio value and total return. The fund invests a majority of its assets in a diversified portfolio of taxable municipal securities.

About BWAY BrainsWay Ltd.

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

Share on Social Networks: